Xtant Medical Stock Price, News & Analysis

Xtant Medical Holdings (NYSE American: XTNT) has entered a securities purchase agreement to sell approximately $9.75 million in common stock and warrants to accredited investors, led by Stavros Vizirgianakis, who will become Non-Executive Chairman. The transaction involves the sale of around 20.3 million shares at $0.48 each, with a two-tranche closing process. The first closing is expected on August 26, 2022, with the second planned for October 2022. Proceeds will be used for working capital and corporate purposes. The securities are being offered under SEC exemptions.

Xtant Medical Holdings, Inc. (XTNT) reported a second quarter revenue of $15.3 million, marking a 2% increase year-over-year. The company’s biologics segment showed strong growth, up 8%, driven by new product demand. However, gross margin decreased to 54.8% from 63.5% due to higher costs and inventory charges. The net loss widened to $1.7 million, or $0.02 per share, compared to $0.7 million in Q2 2021. Despite challenges from supply chain issues, Xtant remains optimistic about future growth, with strategic initiatives gaining traction.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) is set to announce its financial results for the second quarter ended June 30, 2022, on August 4, 2022, before market opening. The earnings conference call will occur at 9:00 AM ET, hosted by CEO Sean Browne and CFO Scott Neils. The company specializes in surgical solutions for spinal disorders, focusing on a broad range of orthobiologics and spinal implant systems. Following the call, a replay will be accessible on their website under ‘Investor Info’.

Xtant Medical Holdings reported a 3% revenue increase to $13.0 million for Q1 2022, up from $12.5 million in Q1 2021. The biologics segment saw a notable 13% year-over-year growth, driven by new product launches and expanded distribution. However, gross margin decreased to 58.3% from 64.5% due to higher production costs and a shift in sales mix. Operating expenses rose to $9.4 million, leading to a net loss of $2.2 million, compared to a loss of $29,000 in Q1 2021. Non-GAAP Adjusted EBITDA also worsened to a loss of $0.9 million.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) has appointed Scott Neils as Chief Financial Officer, effective June 1, 2022. Neils, who has over 15 years of experience in public accounting and finance, previously served as the interim CFO since January 3, 2022, and as the company's Controller since August 2019. His extensive experience is expected to support the company’s growth strategy and mission of 'honoring the gift of donation.' The leadership change aims to strengthen financial management amid ongoing challenges in the medical technology sector.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its financial results for Q1 2022 on May 5, 2022, before market open. The conference call to discuss these results will be hosted by CEO Sean Browne and Interim CFO Scott Neils at 9:00 AM ET. Investors can access the call via dial-in or webcast. Xtant specializes in surgical solutions for spinal disorders, focusing on orthobiologics and spinal implant systems for complex spine procedures.

Xtant Medical Holdings (NYSE American: XTNT) has announced that its President and CEO, Sean Browne, will present at the Canaccord Musculoskeletal Conference on March 22, 2022, at 2:00 p.m. CT in Chicago. The presentation will focus on the company’s innovative surgical solutions for spinal disorders. Investors can access a live webcast through the company’s website, with a replay available for 90 days post-event. Xtant specializes in orthobiologics and spinal implant systems aimed at enhancing spinal fusion in complex and degenerative procedures.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported financial results for the fourth quarter and full year ended December 31, 2021. The company achieved 4% year-over-year revenue growth, totaling $55.3 million for 2021, driven by private label and OEM orthobiologics sales. The fourth quarter revenue remained stable at $14.0 million. However, gross margin decreased to 55.1% from 64.1% in Q4 2020. Operating expenses rose to $9.6 million in Q4. The net loss for the year improved to $4.8 million, compared to $7.0 million in 2020.

Xtant Medical Holdings (NYSE American: XTNT) will release its financial results for Q4 and the full year ending December 31, 2021, on March 8, 2022, before market open. CEO Sean Browne and Interim CFO Scott Neils will discuss the results in a conference call scheduled for the same day at 9:00 AM ET. Investors can access the call by dialing 877-407-6184 or internationally at 201-389-0877. A replay will be available on their website post-call.